 |
|
Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
September 24, 2009A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award. The prestigious prize carries with it funding for total costs of up to $4.7 million over five years, and is designed to support the work of exceptionally creative scientists, whose novel proposals offer the potential to make extraordinary contributions to human health.
Hilde Cheroutre, Ph.D., received the award during the Pioneer Award Symposium today at the NIH headquarters in Bethesda, Maryland. NIH Director Francis S. Collins, M.D., Ph.D., announced the winners. Dr. Cheroutre is one of a select group of 18 scientists nationwide chosen for the 2009 prize from among more than 2,300 applicants. The award will fund her innovative research proposal that, if successful, would create a new way of detecting, treating and possibly preventing autoimmune diseases, with the potential for identifying high risk for autoimmunity in newborns.
In announcing the winners, the NIH said the awards are part of its ongoing efforts to encourage highly creative scientists to explore bold ideas that have the potential to catapult fields forward and speed the translation of research into improved health.
"Leaps in knowledge often result from exceptional minds exploring ideas that were considered risky at their inception, especially in the absence of strong supportive data," said an NIH statement describing the awards. "The changing face of biomedical research calls for support of aggressive risk-taking and innovation that will produce tomorrow's conceptual and technological breakthroughs."
Nilabh Shastri, Ph.D., a prominent scientist and immunology professor at UC Berkeley, who previously worked with Dr. Cheroutre, said her selection "justifies the existence of such awards."
"Dr. Cheroutre possesses a remarkable and rare combination of abilities which have allowed her to make seminal research contributions," said Dr. Shastri, noting that Dr. Cheroutre's previous discoveries have opened up novel avenues of research on the molecular mechanisms of immunological memory, regulatory T cells and autoimmunity. "She not only questions dogmas, but also designs appropriate experiments and has the persistence to carry through until the problems are resolved. She is simply one of the best."
Dr. Cheroutre's proposal focuses on pinpointing specific molecular and genetic events that, she believes, could lay at the basis of susceptibility to autoimmunity. She also will work toward developing innovative treatment, and even more far-reaching approaches, that might prevent autoimmunity in those susceptible individuals. Autoimmunity occurs when the body's white blood cells mistakenly attack normal cells. This leads to a host of disorders such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. "Normally, the immune system provides us protection against pathogens and the generation of transformed cancer cells," said Dr. Cheroutre. "But in autoimmunity, the immune system does not seem to be able to distinguish bad from good cells. It's like the body gets caught in friendly fire. It can cause incredible self-destruction."
If Dr. Cheroutre's premise is correct -- and she proves that certain cellular defects underlie autoimmunity -- it could allow for early detection of those individuals at high risk. "If true, it would enable us to detect at birth whether an individual is genetically prone to autoimmunity."
The second part of her groundbreaking proposal would then come into play through the development of new therapies that could potentially prevent autoimmunity in those people identified as highly susceptible. Theoretically, similar treatments could also be used for those who have already developed autoimmunity.
"If successful, an individual could be treated very early on - right after birth-- to prevent the disease from occurring or they could be closely observed (medically) and the moment they start to show signs of autoimmunity, treatment could begin," said Dr. Cheroutre. "This would enable treatment before autoimmunity starts up and gets out of hand. It is so important to stop or control these diseases before too much damage has occurred. They are kind of like cancer, in that once it gets too far along, it takes a huge toll."
Dr. Cheroutre's bold proposal is not her first venture into unconventional thinking. In fact, she is a world renowned expert on mucosal immunity, whose findings over the years have frequently bucked conventional wisdom on the immunology of the intestines or broken new ground in immunology in general. Such was her 2007 discovery that retinoic acid, a vitamin A derivative, can play a critical role in controlling inflammation in the body, which is the chief cause of inflammatory bowel disease, rheumatoid arthritis and several other autoimmune diseases. Nature Medicine named it one of the key biomedical research advances of the year. The finding was a departure from current understanding and opened a new frontier in inflammation research.
This, of course, is just the kind of researcher the NIH is looking for with its Pioneer award. The NIH selects the recipients through a special application and evaluation process. Distinguished outside experts identify the most highly competitive applicants. The Advisory Committee to the Director, NIH, performs the second level of review and Dr. Collins makes final decisions based on the outside evaluations and programmatic considerations.
Unlike the predominant form of NIH research grants that require heavy documentation and significant preliminary data, the Pioneer award does not seek pre-existing data from applicants, since they are dealing with novel concepts that have not yet been tested. Instead, the selection committee looks for highly creative proposals put forth by exemplary researchers, along with proof of past innovation and a record of success.
Dr. Cheroutre said her proposal is based on logic, reason and previous information she garnered in her studies of the mucosal immune system. "It really is my knowledge from the mucosal immune system, and the mechanisms by which the body chooses to tolerate or attack certain substances, that I used to reason and make this proposal," she said.
Dr. Cheroutre finds the Pioneer award both exhilarating and challenging. "The NIH is giving recipients the chance to explore our most imaginative concepts. It's a once in a lifetime opportunity. I hope that the opportunity given to me with this award will ultimately lead to innovative and advanced knowledge that can help to prevent autoimmunity from occurring and effectively treat those people who already suffer from autoimmune diseases."
La Jolla Institute for Allergy and Immunology
"Leaps in knowledge often result from exceptional minds exploring ideas that were considered risky at their inception, especially in the absence of strong supportive data," said an NIH statement describing the awards. "The changing face of biomedical research calls for support of aggressive risk-taking and innovation that will produce tomorrow's conceptual and technological breakthroughs."
Nilabh Shastri, Ph.D., a prominent scientist and immunology professor at UC Berkeley, who previously worked with Dr. Cheroutre, said her selection "justifies the existence of such awards."
"Dr. Cheroutre possesses a remarkable and rare combination of abilities which have allowed her to make seminal research contributions," said Dr. Shastri, noting that Dr. Cheroutre's previous discoveries have opened up novel avenues of research on the molecular mechanisms of immunological memory, regulatory T cells and autoimmunity. "She not only questions dogmas, but also designs appropriate experiments and has the persistence to carry through until the problems are resolved. She is simply one of the best."
Dr. Cheroutre's proposal focuses on pinpointing specific molecular and genetic events that, she believes, could lay at the basis of susceptibility to autoimmunity. She also will work toward developing innovative treatment, and even more far-reaching approaches, that might prevent autoimmunity in those susceptible individuals. Autoimmunity occurs when the body's white blood cells mistakenly attack normal cells. This leads to a host of disorders such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis. "Normally, the immune system provides us protection against pathogens and the generation of transformed cancer cells," said Dr. Cheroutre. "But in autoimmunity, the immune system does not seem to be able to distinguish bad from good cells. It's like the body gets caught in friendly fire. It can cause incredible self-destruction."
If Dr. Cheroutre's premise is correct -- and she proves that certain cellular defects underlie autoimmunity -- it could allow for early detection of those individuals at high risk. "If true, it would enable us to detect at birth whether an individual is genetically prone to autoimmunity."
The second part of her groundbreaking proposal would then come into play through the development of new therapies that could potentially prevent autoimmunity in those people identified as highly susceptible. Theoretically, similar treatments could also be used for those who have already developed autoimmunity.
"If successful, an individual could be treated very early on - right after birth-- to prevent the disease from occurring or they could be closely observed (medically) and the moment they start to show signs of autoimmunity, treatment could begin," said Dr. Cheroutre. "This would enable treatment before autoimmunity starts up and gets out of hand. It is so important to stop or control these diseases before too much damage has occurred. They are kind of like cancer, in that once it gets too far along, it takes a huge toll."
Dr. Cheroutre's bold proposal is not her first venture into unconventional thinking. In fact, she is a world renowned expert on mucosal immunity, whose findings over the years have frequently bucked conventional wisdom on the immunology of the intestines or broken new ground in immunology in general. Such was her 2007 discovery that retinoic acid, a vitamin A derivative, can play a critical role in controlling inflammation in the body, which is the chief cause of inflammatory bowel disease, rheumatoid arthritis and several other autoimmune diseases. Nature Medicine named it one of the key biomedical research advances of the year. The finding was a departure from current understanding and opened a new frontier in inflammation research.
This, of course, is just the kind of researcher the NIH is looking for with its Pioneer award. The NIH selects the recipients through a special application and evaluation process. Distinguished outside experts identify the most highly competitive applicants. The Advisory Committee to the Director, NIH, performs the second level of review and Dr. Collins makes final decisions based on the outside evaluations and programmatic considerations.
Unlike the predominant form of NIH research grants that require heavy documentation and significant preliminary data, the Pioneer award does not seek pre-existing data from applicants, since they are dealing with novel concepts that have not yet been tested. Instead, the selection committee looks for highly creative proposals put forth by exemplary researchers, along with proof of past innovation and a record of success.
Dr. Cheroutre said her proposal is based on logic, reason and previous information she garnered in her studies of the mucosal immune system. "It really is my knowledge from the mucosal immune system, and the mechanisms by which the body chooses to tolerate or attack certain substances, that I used to reason and make this proposal," she said.
Dr. Cheroutre finds the Pioneer award both exhilarating and challenging. "The NIH is giving recipients the chance to explore our most imaginative concepts. It's a once in a lifetime opportunity. I hope that the opportunity given to me with this award will ultimately lead to innovative and advanced knowledge that can help to prevent autoimmunity from occurring and effectively treat those people who already suffer from autoimmune diseases."
La Jolla Institute for Allergy and Immunology
Autoimmunity Current Events and Autoimmunity News RSSStanford study identifies cellular mechanism that causes lupuslike symptoms in mice
Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.
Autoimmune response can induce pancreatic tumor rejection
Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.
Pitt researchers find promising candidate protein for cancer prevention vaccines
Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers.
Sun exposure may trigger certain autoimmune diseases in women
Ultraviolet (UV) radiation from sunlight may be associated with the development of certain autoimmune diseases, particularly in women.
Study aims to induce recovery from ankylosing spondylitis
Chinese patients will soon have the opportunity to take part in a study of a novel therapy aimed at reversing the autoimmune disease, ankylosing spondylitis.
Gene regulates immune cells' ability to harm the body
A recently identified gene allows immune cells to start the self-destructive processes thought to underlie autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis.
Investigation finds that cigarette smoking does not affect everyone in same way
Cigarette smoking induced COPD, or chronic obstructive pulmonary disease, is a disease that results in severe breathing difficulty.
Omega fatty acid balance can alter immunity and gene expression
For the past century, changes in the Western diet have altered the consumption of omega-6 fatty acids (w6, found in meat and vegetable oils) compared with omega-3 fatty acids (w3, found in flax and fish oil).
Two targeted therapies likely better than one in patients with aggressive lymphoma
When combined with a cocktail of chemotherapy drugs, two monoclonal antibodies, instead of one, appear to offer superior results in patients with diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG).
Genetic study confirms the immune system's role in narcolepsy
Scientists funded by the National Institutes of Health have identified a gene associated with narcolepsy, a disorder that causes disabling daytime sleepiness, sleep attacks, irresistible bouts of sleep that can strike at any time, and disturbed sleep at night.
More Autoimmunity Current Events and Autoimmunity News Articles
 |
Autoantibodies and Autoimmunity: Molecular Mechanisms in Health and Disease by Kenneth Michael Pollard (Editor) This is the first book to address all aspects of the biology of autoantibodies in a single volume, including a discussion of immunology, experimental models, clinical aspects, and the use of autoantibodies as probes in molecular and cellular biology. The editor, currently professor at the W.M. Keck Autoimmune Disease Center of The Scripps Research Institute, has assembled an all-star team of authors to report on the latest research, technologies, and applications. Following an introductory chapter, the book goes on to cover such topics as cellular mechanisms of autoantibody production, clinical and diagnostic usefulness in human disease, and animal models used to study the elicitation of autoantibodies. The whole is rounded off with a look at future perspectives. With its... |
 |
Current Concepts in Autoimmunity and Chronic Inflammation (Current Topics in Microbiology and Immunology) by A. Radbruch (Editor), P.E. Lipsky (Editor) The ethiopathologies of autoimmune diseases are complex. A broad variety of cell types and gene products are involved. However, clinical and experimental evidence suggests that the importance of an individual factor changes during the course of the disease. Factors and cell types that induce acute autoreactivity and initiate an autoimmune disease could be distinct from those that drive a chronic course of that disease. |
 |
The Autoimmune Epidemic by Donna Jackson Nakazawa (Author), Dr. Douglas Kerr (Foreword) From the foreword by Dr. Douglas Kerr, Director, Johns Hopkins Transverse Myelitis Center "The Autoimmune Epidemic by Donna Jackson Nakazawa is an astounding book....It is the kind of book that will rivet you and scare you. It will make you angry. It will amaze you with the courage of some of the people described in the book...The Autoimmune Epidemic is every bit as compelling as Upton Sinclair's The Jungle...It is also every bit as necessary as An Inconvenient Truth.... You will leave this book with no reservations about the veracity of the conclusions: put simply, there is no doubt that autoimmune diseases are on the rise and increasing environmental exposures of toxins and chemicals is fueling this rise. The research is sound. The conclusions unassailable.... Reading The... |
 |
Thyroid Autoimmunity and Conditions Audio Jim Lowrance (Primary Contributor) |
 |
Surviving the Autoimmunity Challenge by John Merchant (Author) |
|
The Quantal Theory of Immunity: The Molecular Basis of Autoimmunity, Leukemia and Vaccines by Kendall A. Smith (Author) This book explains how the immune system functions, namely, how individual cells of the immune system make the decision to respond or not to respond to foreign microbes and molecules, and how the critical molecules function to trigger the cellular reactions in an all-or-none (quantal) manner. To date, there has not been a complete description of the immune system and its cells and molecules, primarily because most of the information has accumulated only in the last 40 years and our understanding has been expanding rapidly only in the last 20 years. It is now clear that the cells have evolved a way to count the number of foreign antigenic molecular hits, and they only react when a critical number of events have accumulated. Subsequently, control over the reaction is transferred to a... | |
 |
Allergy, Asthma and Immuology - Meet the Challenge (Discusses Clinical Immunology; Mast Cells, Basophils and Basic Concepts of Mediators; Allergens) Also With: Dr. Joseph Bellanti (Commentary), Dr. Timothy Sullivan (Commentary), Dr. Charles Banov (Commentary) One of the purposes of the American College of Allergy, Asthma and Immunology is to provide meaningful continuing education for its members. In addition to holding annual meetings, the ACAAI has developed a collection of videocassettes to enable particpants to avail themselves of quality continuing education in their home and office settings. This video is a lecture given by three distinguished doctors in their respective fields. Dr. Joseph Bellanti discusses Clinical Immunology - Stem cell reconstitution, reconstitution by T-cell, clones for CMV infection, Cytokines, Human antibodies from recombinatorial library, Silicone breast implants and Connective Tissue disease. Dr. Timothy Sullivan discusses Mast cells, Basophils and Basic Concepts of Mediators . Dr. Charles Banov discusses... |
 |
Autoimmunity: Role, Regulation and Disorders by Fynn L. Vogel (Editor), Lucas F. Zimmermann (Editor), Robert Root-Bernstein (Editor), David J. Blake (Editor), Graham F. Brady (Editor) Autoimmunity is the failure of an organism to recognise its own constituent parts (down to the sub-molecular levels) as self, which results in an immune response against its own cells and tissues. Any disease that results from such an aberrant immune response is termed an auto-immune disease such as the disease multiple sclerosis or heart disease. This book provides new and important research on several auto-immune disorders and their processes. |
 |
Essentials of Immunology and Serology by Delmar Anyone pursuing a career in the medical laboratory will want to have this comprehensive, yet straightforward, text. Essentials of Immunology and Serology doesn't just study the components of the immune system, it covers the way in which these components combine to generate the immune response and how these responses relate to infectious diseases, autoimmunity, tumors, hypersensitivity and transplantation. Covers the application and interpretation of a wide array of medical test kits, unlike other texts that focus only on one outdated procedure. An ideal resource for users pursuing medical lab careers that meets the immunology guidelines of the American Society of Clinical Pathologists. |
|
Molecular and Cellular Mechanisms of Human Hypersensitivity and Autoimmunity by Edward J. Goetzl (Author) A molecular and cellular biological approach to human immuno-deficiency and autoimmunity. Coverage includes descriptions of the cytokines and cellular mediators necessary for integrated and well-regulated immune responses. The antigenic stimuli, histocompatibility variants, lymphocytic defects and effector cell abnormalities central to selected human hypersensitivity and autoimmune diseases are also covered, as are molecular strategies to novel therapies for immune diseases using monoclonal antibodies or receptor-specific immunotoxins. |
| © 2009 BrightSurf.com |